Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2009 - 2026)

Edwards Lifesciences has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $40.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 11.75% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $160.9 million (up 4.96% YoY), and the FY2025 full-year result was $156.6 million, up 0.9% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $40.9 million, down from $42.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $42.7 million in Q4 2025, with the low at $34.1 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $37.5 million, with a median of $36.7 million recorded in 2023.
• Peak annual rise in Depreciation & Amortization (CF) reached 16.08% in 2024, while the deepest fall reached 6.5% in 2024.
• Tracing EW's Depreciation & Amortization (CF) over 5 years: stood at $35.4 million in 2022, then gained by 3.67% to $36.7 million in 2023, then grew by 16.08% to $42.6 million in 2024, then increased by 0.23% to $42.7 million in 2025, then slipped by 4.22% to $40.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $40.9 million (Q1 2026), $42.7 million (Q4 2025), and $39.2 million (Q3 2025), per Business Quant data.

Peer Comparison